ライフサイエンスコーパス: high-density lipoprotein cholesterol

1 were determined by the log of (triglyceride/high-density lipoprotein cholesterol).

2 ait (for example, rs7115089, miR-125b-5p and high-density lipoprotein cholesterol).

3 cholesterol and triglyceride, and increasing high-density lipoprotein cholesterol.

4 effect estimate as large as that of total or high-density lipoprotein cholesterol.

5 s of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol.

6 density lipoprotein cholesterol families) or high-density lipoprotein cholesterol.

7 ociated with TGs, total cholesterol, and non-high-density lipoprotein cholesterol.

8 f low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol.

9 (LOF) mutations in LIPG in individuals with high-density lipoprotein cholesterol.

10 oB), small + medium LDL particles, and total/high-density lipoprotein cholesterol.

11 eese was inversely associated with serum non-high-density lipoprotein cholesterol.

12 y lipoprotein cholesterol, triglycerides, or high-density lipoprotein cholesterol.

13 h diabetes with hypertriglyceridemia and low high-density lipoprotein cholesterol.

14 n part owing to hypertriglyceridemia and low high-density lipoprotein cholesterol.

15 may preferentially improve triglycerides and high-density lipoprotein cholesterol.

16 tolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol.

17 ol, low-density lipoprotein-cholesterol, and high-density lipoprotein-cholesterol.

18 ted QT interval, HR-corrected QT interval or high-density lipoprotein-cholesterol.

19 e sustained programs on agents to raise HDL (high-density lipoprotein) cholesterol.

20 In statin nonusers (n = 71), elevated high-density lipoprotein cholesterol (+0.08 mmol/L; P =

21 triglycerides, but was associated with lower high density lipoprotein cholesterol (-0.014 standard de

22 esterol (0.04 mg/dL; 95% CI, -0.01 to 0.10), high-density lipoprotein cholesterol (-0.01 mg/dL; 95% C

23 (0.70 mmHg; 95% CI = 0.24-1.16) and reduced high-density lipoprotein cholesterol (-0.02 mmol/l; 95%

24 lesterol (1.6 [1.1-2.1]), and borderline low high-density lipoprotein cholesterol (1.4 [1.0-1.8]) rem

25 lipoprotein cholesterol (27.9 to 60.0%), non-high-density lipoprotein cholesterol (10.0 to 36.6%), ap

26 vs placebo were observed at week 12 for non-high-density lipoprotein cholesterol (-10.8% vs 2.3%; di

27 traits within a locus (12 out of 33 loci for high-density lipoprotein cholesterol, 10 of 35 loci for

28 und in 8.6% for total cholesterol, 22.5% for high-density lipoprotein-cholesterol, 12.0% for non-high

29 statistically significantly increased serum high-density lipoprotein cholesterol (13 trials; net cha

30 7 (low-density lipoprotein cholesterol), 8 (high-density lipoprotein cholesterol), 14 (triglycerides

31 showed nominal significant association with high-density lipoprotein cholesterol (2 SNPs), low-densi

32 lycerides (2.67 [95% CI, 2.38-2.95]), or low high-density lipoprotein cholesterol (2.63 [95% CI, 2.33

33 ion led to greater improvements in levels of high-density lipoprotein cholesterol (3.86 mg/dL [to con

34 rol, 109.23 mg/dL (103.68-114.79 mg/dL); for high-density lipoprotein cholesterol, 42.80 mg/dL (39.84

35 .4% smaller waist circumference, 4.4% higher high-density lipoprotein cholesterol, 8.5% lower triglyc

36 nsity lipoprotein-cholesterol, 12.0% for non-high-density lipoprotein-cholesterol, 8.0% for low-densi

37 Starting with non-high-density lipoprotein cholesterol, a surrogate for ve

38 tyrosine, and isoleucine and lower levels of high-density lipoprotein cholesterol, acetate, and apoli

39 ed for LDL-C were observed with achieved non-high-density lipoprotein cholesterol and apolipoprotein

40 est trials of 4 g/d prescription n-3 FA, non-high-density lipoprotein cholesterol and apolipoprotein

41 in enhancers (the strongest effects were for high-density lipoprotein cholesterol and body mass index

42 t association was found for higher levels of high-density lipoprotein cholesterol and decreased preva

43 nonfasting glucose levels; however, reduced high-density lipoprotein cholesterol and elevated C-reac

44 associations of these foods with plasma non-high-density lipoprotein cholesterol and for red and pro

45 er, controlling for biomarkers, particularly high-density lipoprotein cholesterol and glycated hemogl

46 adjusted models, women had higher levels of high-density lipoprotein cholesterol and high-density li

47 cational attainment, exercise, levels of non-high-density lipoprotein cholesterol and high-sensitivit

48 ovariates, no associations of serum total or high-density lipoprotein cholesterol and incident prolif

49 0.458-0.848, P = 0.002), and third-trimester high-density lipoprotein cholesterol and low-density lip

50 e MetS components and CA, except for reduced high-density lipoprotein cholesterol and nonfasting gluc

51 no associations, or inverse associations of high-density lipoprotein cholesterol and total cholester

52 oprotein cholesterol, and ratios of total to high-density lipoprotein cholesterol and triglycerides t

53 -binding globulin), markers of dyslipidemia (high-density lipoprotein cholesterol and triglycerides),

54 ssociated with CVD risk after adjustment for high-density lipoprotein-cholesterol and did not provide

55 evels with body mass index, particularly for high-density lipoprotein-cholesterol and triglycerides (

56 d alcohol and was positively associated with high-density-lipoprotein cholesterol and intakes of poly

57 erol, 71 single-nucleotide polymorphisms for high-density lipoprotein cholesterol, and 40 single-nucl

58 olesterol, the ratio of total cholesterol to high-density lipoprotein cholesterol, and 8-OHdG levels.

59 e relationship between additional LDL-C, non-high-density lipoprotein cholesterol, and apolipoprotein

60 r age, sex, hypertension, smoking, diabetes, high-density lipoprotein cholesterol, and body mass inde

61 c biomarkers, including glycated hemoglobin, high-density lipoprotein cholesterol, and C-reactive pro

62 diastolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, and glucose levels

63 in systolic blood pressure, smoking status, high-density lipoprotein cholesterol, and hemoglobin A(1

64 lic abnormalities (high fasting glucose, low high-density lipoprotein cholesterol, and high triglycer

65 Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and ratios of tota

66 ia, neuroticism, educational attainment, and high-density lipoprotein cholesterol, and significant ne

67 mean concentrations of total cholesterol and high-density lipoprotein cholesterol, and smoking status

68 Total cholesterol, high-density lipoprotein cholesterol, and triglycerides

69 Lipid traits (total, low-density and high-density lipoprotein cholesterol, and triglycerides)

70 ity lipoprotein cholesterol; lower levels of high-density lipoprotein cholesterol; and, to a lesser e

71 CETP inhibition increased plasma high-density lipoprotein cholesterol, apolipoprotein AI,

72 were also observed in total cholesterol, non-high-density lipoprotein cholesterol, apolipoprotein B,

73 ther atherogenic lipid levels, including non-high-density lipoprotein cholesterol, apolipoprotein B,

74 ations of total, low-density lipoprotein, or high-density lipoprotein cholesterol, apolipoproteins A1

75 terol; lipoprotein(a), apolipoprotein B, and high-density lipoprotein cholesterol are largely unaffec

76 for other cardiac risk factors including non-high-density lipoprotein cholesterol at 55 years of age

77 nce, blood pressure, triglycerides, glucose, high-density lipoprotein cholesterol) at 15 (n=512), 16

78 e saw a small increase in rate of change for high-density lipoprotein cholesterol (beta = 0.28 mg/dL;

79 associated in opposite directions with both high-density lipoprotein cholesterol (beta coefficient=-

80 mprove clinical outcomes, despite increasing high-density lipoprotein cholesterol by 30%.

81 ding hypertension, hypertriglyceridemia, low high-density lipoprotein cholesterol, central obesity, a

82 re, body mass index, apolipoprotein A-1, and high-density lipoprotein cholesterol concentration (beta

83 eat was positively associated with serum non-high-density lipoprotein cholesterol concentration and s

84 ted fasting blood glucose concentration, low high-density lipoprotein cholesterol concentration, hype

85 isk factors (body mass index, triglycerides, high-density lipoprotein cholesterol concentrations, and

86 rapy, body mass index, heart rate, total and high-density lipoprotein cholesterol concentrations, smo

87 stment for 14 clinical covariates (including high-density lipoprotein cholesterol content, coronary a

88 tifies 11 variants associated with increased high-density lipoprotein-cholesterol, decreased triglyce

89 markers: fasting glucose, total cholesterol, high-density lipoprotein cholesterol, dehydroepiandroste

90 The magnitude of on-treatment high-density lipoprotein cholesterol difference between

91 re more likely to have high triglyceride/low high-density lipoprotein cholesterol dyslipidemia.

92 -regression for various covariates including high-density lipoprotein cholesterol, each 1 unit of nat

93 carriers, carriers of PTV at CETP had higher high-density lipoprotein cholesterol (effect size, 22.6

94 pectroscopy and a validated ex vivo assay of high-density lipoprotein cholesterol efflux capacity.

95 ssure, ratio of fasting total cholesterol to high-density lipoprotein cholesterol, estimated glomerul

96 ty groups had an increased prevalence of low high-density lipoprotein cholesterol, except for Japanes

97 (systolic blood pressure and ratio of total-high-density lipoprotein cholesterol), family history of

98 aboratory value >/=150 mg/dL), low levels of high-density lipoprotein cholesterol (fasting laboratory

99 abolic biomarkers (diastolic blood pressure, high-density lipoprotein cholesterol, fasting and 2-hour

100 We apply MASTOR to data on high-density lipoprotein cholesterol from the Framingham

101 de association studies (from 3.6 to 7.6% for high-density lipoprotein cholesterol, from 5.0 to 8.8% f

102 vascular risk factors (pulse pressure, total/high density lipoprotein cholesterol, glycosylated hemog

103 low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol goals in secondary

104 Neither low- nor high-density lipoprotein cholesterol GRS was significant

105 een duration of moderate hyperlipidemia (non-high-density lipoprotein cholesterol >/= 160 mg/dL) in e

106 oprotein cholesterol (LDL-C) <160 mg/dl, and high-density lipoprotein cholesterol >/=40 mg/dl.

107 w-density lipoprotein cholesterol <85 mg/dl, high-density lipoprotein cholesterol >40 mg/dl, and trig

108 ty lipoprotein cholesterol >=70 mg/dL or non-high-density lipoprotein cholesterol >=100 mg/dL despite

109 rotein cholesterol (LDL-C) >=70 mg/dl or non-high-density lipoprotein cholesterol >=100 mg/dl to evol

110 in cholesterol (LDL-C) level >=70 mg/dl, non-high-density lipoprotein cholesterol >=100 mg/dl, or apo

111 High-density lipoprotein cholesterol had no significant

112 Total serum and high-density lipoprotein cholesterol have been considere

113 exposure to even moderate elevations in non-high-density lipoprotein cholesterol have elevated risk

114 We predicted height, high density lipoprotein cholesterol (HDL) and body mass

115 ipid scores specific for triglycerides (TG), high density lipoprotein cholesterol (HDL), low density

116 low density lipoprotein cholesterol (LDL-c), high density lipoprotein cholesterol (HDL-c) and triglyc

117 This study asks if elevating plasma high density lipoprotein cholesterol (HDL-C) levels by i

118 High density lipoprotein cholesterol (HDL-C), low densit

119 ively polar CETP inhibitor 26 showing robust high density lipoprotein-cholesterol (HDL-C) elevation a

120 MI), smoking, and total cholesterol (TC) and high-density lipoprotein cholesterol (HDL).

121 ded the triple goals of LDL-C <70 mg/dl, non-high-density lipoprotein cholesterol (HDL-C) <100 mg/dl,

122 s of total cholesterol (TC) (>/= 200 mg/dL), high-density lipoprotein cholesterol (HDL-C) (<40 mg/dL)

123 associated with CVD risk factors, including high-density lipoprotein cholesterol (HDL-C) (beta 0.40,

124 per 10 mg/dl [0.11 mmol/l]; p < 0.001), non-high-density lipoprotein cholesterol (HDL-C) (HR: 1.05;

125 acylglycerols (TAG) (p = 3.18 x 10(-42)) and high-density lipoprotein cholesterol (HDL-C) (p = 1.35 x

126 rs have been shown to substantially increase high-density lipoprotein cholesterol (HDL-C) and apolipo

127 Although the inverse association between high-density lipoprotein cholesterol (HDL-C) and risk of

128 y artery disease (CAD), but the relevance of high-density lipoprotein cholesterol (HDL-C) and triglyc

129 High-density lipoprotein cholesterol (HDL-C) and triglyc

130 Low levels of high-density lipoprotein cholesterol (HDL-C) are common

131 The prognostic importance of high-density lipoprotein cholesterol (HDL-C) as a specif

132 ipoprotein cholesterol (LDL-C) and increased high-density lipoprotein cholesterol (HDL-C) compared wi

133 Plasma levels of high-density lipoprotein cholesterol (HDL-C) decline dra

134 LDL-c from 155 to 128 mg/dL (P < .001), and high-density lipoprotein cholesterol (HDL-c) from 50.3 t

135 ational epidemiologic studies, higher plasma high-density lipoprotein cholesterol (HDL-C) has been as

136 terventions targeting triglycerides (TGs) or high-density lipoprotein cholesterol (HDL-C) have produc

137 hibition of EL will lead to sustained plasma high-density lipoprotein cholesterol (HDL-C) increase an

138 cause of ischemic stroke, and a low level of high-density lipoprotein cholesterol (HDL-C) is also con

139 High-density lipoprotein cholesterol (HDL-C) is an indep

140 diet only), red wine significantly increased high-density lipoprotein cholesterol (HDL-C) level by 0.

141 function of age, age at initiation, and non-high-density lipoprotein cholesterol (HDL-C) level on th

142 ubfamily A, member 1 (ABCA1) and circulating high-density lipoprotein cholesterol (HDL-C) levels in v

143 Total cholesterol and high-density lipoprotein cholesterol (HDL-C) measurement

144 B type 1 (SCARB1) plays an important role in high-density lipoprotein cholesterol (HDL-C) metabolism

145 % of children aged 9-11 years had either low high-density lipoprotein cholesterol (HDL-C) or high non

146 -density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were either

147 m triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-de

148 low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and trigly

149 d these variants for association with LDL-C, high-density lipoprotein cholesterol (HDL-C), and trigly

150 low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and trigly

151 Differences in mean high-density lipoprotein cholesterol (HDL-C), LDL-C, and

152 Levels of serum cholesterol, high-density lipoprotein cholesterol (HDL-C), low-densit

153 cted genetic instruments for blood levels of high-density lipoprotein cholesterol (HDL-C), low-densit

154 poraneously assayed total serum cholesterol, high-density lipoprotein cholesterol (HDL-C), low-densit

155 preeclampsia and maternal total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-densit

156 High-density lipoprotein cholesterol (HDL-C), low-densit

157 ol levels, including total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-densit

158 a small, and chitosan an impressive rise in high-density lipoprotein cholesterol (HDL-C).

159 variants at the GALNT2 locus associated with high-density lipoprotein cholesterol (HDL-C).

160 isk, hypertriglyceridemia, and low levels of high-density lipoprotein cholesterol (HDL-C).

161 th increased cardiovascular risk and reduced high-density lipoprotein cholesterol (HDL-c).

162 NAFLD, such as hypertriglyceridemia and low high-density lipoprotein cholesterol (HDL-C).

163 vels of TRAP, was positively associated with high-density lipoprotein cholesterol (HDL-C; beta = 8.36

164 ated locus associated with triglycerides and high-density lipoprotein cholesterol (HDL-C; cg27243685;

165 y lipoprotein cholesterol (LDL-cholesterol), high-density lipoprotein cholesterol (HDL-cholesterol),

166 tive epidemiological studies have shown that high-density lipoprotein-cholesterol (HDL-C) levels are

167 ociations of triglyceride, total cholesterol/high-density lipoprotein-cholesterol (HDL-C) ratio, HDL-

168 miR-223 was found to regulate high-density lipoprotein-cholesterol (HDL-C) uptake, thr

169 ic (SBP) and diastolic blood pressure (DBP), high-density-lipoprotein cholesterol (HDL-C), and glycat

170 ntly associated with total cholesterol (TC), high-density-lipoprotein cholesterol (HDL-C), low-densit

171 low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], and trigly

172 ores (GRSs) for four blood lipid phenotypes (high-density lipoprotein cholesterol [HDL-c], low-densit

173 asting lipid fractions (triglycerides [TGs], high-density lipoprotein cholesterol [HDL-C], low-densit

174 nterestingly, significantly higher levels of high density lipoprotein cholesterol (HDLc) were observe

175 low-density lipoprotein cholesterol (LDLc), high-density lipoprotein cholesterol (HDLc) and triglyce

176 Low levels of high-density lipoprotein cholesterol (HDLc) have been as

177 brinogen, white blood cell count, vitamin D, high-density lipoprotein cholesterol), healthier lifesty

178 dominal obesity, elevated triglycerides, low high-density lipoprotein cholesterol, high blood pressur

179 high blood pressure, high triglycerides, low high-density lipoprotein cholesterol, high C-reactive pr

180 e rs58542926 variant was not associated with high-density lipoprotein cholesterol in a large sample (

181 ansaminase, white blood cell count and lower high-density lipoprotein cholesterol in men, and with hi

182 sure, and triglyceride levels, decreased and high-density lipoprotein cholesterol increased more afte

183 lesterol (decreased in LFHC group only), and high-density lipoprotein cholesterol (increased in VHFLC

184 on between nuts and hypertriglyceridemia and high-density lipoprotein cholesterol is not well establi

185 25(OH)D levels, whereas genetically reduced high-density lipoprotein-cholesterol is not associated w

186 L cholesterol and lipoprotein (a) and raises high-density lipoprotein cholesterol, it has adverse eff

187 ity lipoprotein cholesterol level <70 mg/dL, high-density lipoprotein cholesterol level >50 mg/dL [wo

188 ), triglyceride level (-40%, -29%, and -8%), high-density lipoprotein cholesterol level (32%, 30%, an

189 Changes in high-density lipoprotein cholesterol level (mean [SD] le

190 holesterol and triglyceride levels and lower high-density lipoprotein cholesterol level are causal ri

191 oded by the CNR1 gene--is known to influence high-density lipoprotein cholesterol level as well, huma

192 High high-density lipoprotein cholesterol level during third

193 By testing each variant for association with high-density lipoprotein cholesterol level in a clinical

194 f at least 70 mg/dL or a final screening non-high-density lipoprotein cholesterol level of at least 1

195 physical activity, total cholesterol level, high-density lipoprotein cholesterol level, systolic blo

196 ely associated with treated hypertension and high-density lipoprotein cholesterol level.

197 ted to physical or mental stress; and higher high-density lipoprotein cholesterol level.

198 c features, decreased stature, and decreased high density lipoprotein cholesterol levels.

199 .7 versus 134.6 to 141.3 mg/dL), >20% higher high-density lipoprotein cholesterol levels (geometric m

200 ice lacking T39 (T39(-/-)) display increased high-density lipoprotein cholesterol levels associated w

201 ion carriers had significantly higher plasma high-density lipoprotein cholesterol levels compared wit

202 Low- and high-density lipoprotein cholesterol levels improved and

203 il counts decreased, hemoglobin and low- and high-density lipoprotein cholesterol levels increased, a

204 iglyceride levels greater than 204 mg/dL and high-density lipoprotein cholesterol levels less than 34

205 Cystatin C levels were positively and plasma high-density lipoprotein cholesterol levels negatively a

206 specially the third-trimester, the effect of high-density lipoprotein cholesterol levels on the risk

207 eding 7 to 90 days, type 2 diabetes, and low high-density lipoprotein cholesterol levels were eligibl

208 High-density lipoprotein cholesterol levels were inverse

209 For example, obesity and lower high-density lipoprotein cholesterol levels were positiv

210 s were also more likely to smoke, have lower high-density lipoprotein cholesterol levels, and have hi

211 rglycemia, elevated triglyceride levels, low high-density lipoprotein cholesterol levels, high blood

212 s in total, low-density lipoprotein, and non-high-density lipoprotein cholesterol levels, in triglyce

213 coronary syndrome, type 2 diabetes, and low high-density lipoprotein cholesterol levels, the selecti

214 djusting for age, race, sex, low-density and high-density lipoprotein cholesterol levels, triglycerid

215 lyceride levels in the plasma while reducing high-density lipoprotein cholesterol levels.

216 ype 1 cannabinoid receptor blockers increase high-density lipoprotein cholesterol levels.

217 w-density lipoprotein (LDL) cholesterol, and high-density lipoprotein cholesterol levels.

218 In contrast, a halving in high-density lipoprotein-cholesterol levels was observat

219 ations, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, lipid-lowering med

220 ntly reduced levels of apolipoprotein B, non-high-density lipoprotein cholesterol, lipoprotein(a), an

221 ent for low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, lipoprotein(a), tr

222 or remnant cholesterol, and -8 mg/dl for non-high-density lipoprotein cholesterol; lipoprotein(a), ap

223 High-density lipoprotein cholesterol, low-density lipopr

224 ture mapping analysis for total cholesterol, high-density lipoprotein cholesterol, low-density lipopr

225 e-mapping analysis that were associated with high-density lipoprotein cholesterol, low-density lipopr

226 -wide DNA methylation and blood lipid levels high-density lipoprotein cholesterol, low-density lipopr

227 bilirubin, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipopr

228 sing data set quartiles of total cholesterol/high-density lipoprotein cholesterol, low-density lipopr

229 index, body fat percentage, lean body mass, high-density lipoprotein cholesterol, low-density lipopr

230 , diastolic blood pressure, fasting glucose, high-density lipoprotein cholesterol, low-density lipopr

231 rs, carriers of PTV at CETP displayed higher high-density lipoprotein cholesterol, lower low-density

232 s of total, low-density lipoprotein, and non-high-density lipoprotein cholesterol; lower levels of hi

233 ein cholesterol >/= 3.36 mmol/L (130 mg/dL), high-density lipoprotein cholesterol <1.03 mmol/L (40 mg

234 events and control of 6 RFs (no smoking, non-high-density lipoprotein cholesterol <130 mg/dl, triglyc

235 4%; 95% CI -17.31%, -12.57%; p < 0.001), non-high-density lipoprotein cholesterol (MD -18.17%; 95% CI

236 15.18%; 95% CI -17.41%, -12.95%; p < 0.001), high-density lipoprotein cholesterol (MD -5.83%; 95% CI

237 95% CI: 0.05, 0.19 mmol/L; P = 0.0001), and high-density lipoprotein cholesterol (MD: 0.02 mmol/L; 9

238 es (n=7603; beta=-71.20; P=0.007) and higher high-density lipoprotein cholesterol (n=8891; beta=15.65

239 Non-high-density lipoprotein cholesterol (NHDL-C), apolipopr

240 Extended elevations of non-high-density lipoprotein cholesterol (non-HDL-C) across

241 cholesterol (LDL-C), triglycerides, and non-high-density lipoprotein cholesterol (non-HDL-C) present

242 sity lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) were si

243 t also LDL-related biomarkers, including non-high-density lipoprotein cholesterol (non-HDL-C), apolip

244 ETC-1002 also lowered non-high-density lipoprotein cholesterol (non-HDL-C), apolip

245 pulation attributable fractions for SBP, non-high-density lipoprotein cholesterol (non-HDL-C), diabet

246 density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), or apo

247 nsity lipoprotein cholesterol (LDL-C) or non-high-density lipoprotein cholesterol (non-HDL-C).

248 ompared with controls, despite no changes in high-density lipoprotein cholesterol or other circulatin

249 visceral fat mass, high blood pressure, low high-density-lipoprotein cholesterol or high triglycerid

250 ith >/= 5 births had the highest odds of low high-density lipoprotein cholesterol (OR, 1.5; 95% confi

251 ol, low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or low-density lip

252 ences were found for fasting plasma glucose, high-density lipoprotein cholesterol, or triglycerides w

253 sterol, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol, or triglyceride, 4

254 lipoprotein cholesterol, and HbA1c and lower high-density lipoprotein cholesterol (P < 0.001 for all)

255 sex (p = 0.02), body mass index (p = 0.01), high-density lipoprotein cholesterol (p = 0.005), N-term

256 sedentary time was associated with decreased high-density lipoprotein cholesterol (P=0.04), and incre

257 leukin-10 remained persistently elevated and high-density lipoprotein cholesterol persistently depres

258 epatitis A), biochemical (e.g., carotenoids, high-density lipoprotein cholesterol), physiological (e.

259 lood pressure, suboptimal triglycerides, and high-density lipoprotein-cholesterol prevalence have cor

260 largely explained by lowering of non-HDL-C (high-density lipoprotein cholesterol), rather than incre

261 -11.3% and -13.6%), and total cholesterol to high-density lipoprotein cholesterol ratio (-5.6% and -8

262 h ARIC metabolic phenotypes, including total:high-density lipoprotein cholesterol ratio (rG=-0.44, P=

263 vents, digoxin use, and total cholesterol to high-density lipoprotein cholesterol ratio were associat

264 e were 1.90 (95% CI, 1.30-2.76) for total to high-density lipoprotein cholesterol ratio, 2.59 (95% CI

265 ded risk factors were body mass index, total:high-density lipoprotein cholesterol ratio, and systolic

266 We aimed to determine whether the total to high-density lipoprotein cholesterol ratio, high-sensiti

267 cholesterol concentrations, and low-density:high-density lipoprotein cholesterol ratio.

268 lin resistance), serum-triglyceride-to-serum-high-density lipoprotein-cholesterol ratio TG/HDL-C, or

269 ociations were also identified (eg, total-to-high-density-lipoprotein cholesterol ratio: b = -0.22 pe

270 and years of schooling (rG=0.18, s.e.=0.03), high-density lipoprotein cholesterol (rG=0.28, s.e.=0.05

271 CI, 1.11-1.94]), an elevated serum level of high-density lipoprotein cholesterol (RR per 1-SD increa

272 Reduced high-density lipoprotein cholesterol showed no significa

273 Total and high-density lipoprotein cholesterol similarly increased

274 , sex, systolic blood pressure, cholesterol, high-density lipoprotein cholesterol, smoking, prevalent

275 s such as waist circumference, triglyceride, high-density lipoprotein cholesterol, systolic and diast

276 tories for low-density lipoprotein (LDL) and high-density lipoprotein cholesterols, systolic and dias

277 The total cholesterol to high-density lipoprotein cholesterol (TC/HDL-C) ratio, e

278 enzymatic activity and a 35% increase of the high density lipoprotein cholesterol that was observed u

279 gene, TEAD2, is found to be associated with high-density lipoprotein cholesterol through gene-based

280 to decrease low-density lipoprotein and non-high-density lipoprotein cholesterol to specific target

281 physical activity, smoking, alcohol intake, high-density lipoprotein-cholesterol, total cholesterol,

282 ased fatty liver index (FLI)], dyslipidemia (high-density lipoprotein cholesterol, triglycerides), in

283 Changes in blood pressure, high-density lipoprotein cholesterol, triglycerides, and

284 and fasting blood sample (total cholesterol, high-density lipoprotein cholesterol, triglycerides, glu

285 actors: low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, typ

286 ypes of MDD with changes of fasting glucose, high-density lipoprotein-cholesterol, triglycerides, sys

287 notypes: V(G)/V(p)=31.4%, P<3.1x10(-11)) and high-density lipoprotein cholesterol (V(G)/V(p)=26.4%, P

288 rable objective biomarkers (concentration of high-density lipoprotein cholesterol, vitamin D and C-re

289 oteins, the RR per 1-mmol/L reduction in non-high-density lipoprotein cholesterol was 0.79 (95% CI, 0

290 5; 95% CI, 1.05-1.26), while a high level of high-density lipoprotein cholesterol was protective (aOR

291 than in WT mice (2.6 versus 0.4 mmol/L), and high-density lipoprotein cholesterol was significantly l

292 High levels of high-density lipoprotein cholesterol were associated wit

293 lipoprotein cholesterol and triglycerides to high-density lipoprotein cholesterol were calculated.

294 us, smoking, higher triglycerides, and lower high-density lipoprotein cholesterol were more prevalent

295 s with CV disease and low baseline levels of high-density lipoprotein cholesterol were randomized to

296 ticles, whereas small + medium LDL and total/high-density lipoprotein cholesterol were unaffected by

297 tion between CCR2 and CX3CR1 expressions and high-density lipoprotein-cholesterol, whereas CCR5 expre

298 of higher systolic blood pressure and lower high-density lipoprotein cholesterol with Carotid artery

299 relationship of differences in on-treatment high-density lipoprotein cholesterol with the magnitude

300 t results were found for decreased levels of high-density lipoprotein cholesterol, with ORs of 2.97 (